Results 1 to 10 of about 241,371 (303)

Eupatilin-derived compounds enhance antitumor activity and doxorubicin efficacy in triple-negative breast cancer [PDF]

Frontiers in Oncology
PurposeTriple-negative breast cancer (TNBC) has limited therapeutic options. We evaluated the anticancer activities of the Eupatilin derivatives ONG41008 and ONG41003 and their potential to enhance doxorubicin efficacy.Materials and methodsAnticancer ...
Choong-Jae Lee, Choong-Jae Lee, Jinyoung Park, Yanghee Choi, Sung Hoon Sim, Sun-Young Kong, Sun-Young Kong, Sun-Young Kong   +7 more
doaj   +2 more sources

Dapagliflozin May Protect Against Doxorubicin-Induced Cardiotoxicity

Anatolian Journal of Cardiology, 2023
Background: Doxorubicin is a widely used agent in the treatment of cancer, but the cardiotoxicity associated with this drug limits its potential for use.
Sebahat Ulusan, Kanat Gülle, Ahmet Peynirci, Murat Sevimli, Adnan Karaibrahimoglu, Mevlüt Serdar Kuyumcu   +5 more
doaj   +1 more source

Exercise Training Preserves Myocardial Strain and Improves Exercise Tolerance in Doxorubicin-Induced Cardiotoxicity

Frontiers in Cardiovascular Medicine, 2021
Doxorubicin causes cardiotoxicity and exercise intolerance. Pre-conditioning exercise training seems to prevent doxorubicin-induced cardiac damage.
Igor L. Gomes-Santos, Camila P. Jordão, Clevia S. Passos, Patricia C. Brum, Edilamar M. Oliveira, Roger Chammas, Anamaria A. Camargo, Carlos E. Negrão, Carlos E. Negrão   +8 more
doaj   +1 more source

IFN-γ/Doxorubicin Complex Nanoparticles for Enhancing Therapy in the Context of Human Ovarian Carcinoma

Frontiers in Materials, 2022
The cytokine interferon gamma (IFN-γ) and doxorubicin mono-therapy has been approved by the Food and Drug Administration (FDA) for the treatment of tumors.
Rongyuan Yi, Wanwan Lv, Shan Zheng, Ningyu Zhang, Yuheng Zhang, Kai Yang, Tuo Huang, Yanning Yang, Hui Chu, Jian Chen   +9 more
doaj   +1 more source

Diosmin Alleviates Doxorubicin-Induced Liver Injury via Modulation of Oxidative Stress-Mediated Hepatic Inflammation and Apoptosis via NfkB and MAPK Pathway: A Preclinical Study

Antioxidants, 2021
Hepatotoxicity caused by chemotherapeutic drugs (e.g., doxorubicin) is of critical concern in cancer therapy. This study focused on investigating the modulatory effects of diosmin against doxorubicin-induced hepatotoxicity in Male Wistar rats.
Abdullah F. AlAsmari, Metab Alharbi, Faleh Alqahtani, Fawaz Alasmari, Mohammed AlSwayyed, Sami I. Alzarea, Ibrahim A. Al-Alallah, Adel Alghamdi, Hassan M. Hakami, Meshal K. Alyousef, Youssef Sari, Nemat Ali   +11 more
doaj   +1 more source

Zymosan A Improved Doxorubicin‐Induced Ventricular Remodeling by Evoking Heightened Cardiac Inflammatory Responses and Healing in Mice

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2023
Background Doxorubicin‐induced myocardial injury is reflected by the presence of vacuolization in both clinical and animal models. The lack of scar tissue to replace the vacuolizated cardiomyocytes indicates that insufficient cardiac inflammation and ...
Guiwen Xu, Zhujing Hao, Wei Xiao, Ruopeng Tan, Mengyang Yuan, Yunlong Xia, Yang Liu   +6 more
doaj   +1 more source

Repeated Remote Ischemic Conditioning Reduces Doxorubicin-Induced Cardiotoxicity

JACC. CardioOncology, 2020
Objectives: This study investigated the cardioprotective effect of repeated remote ischemic preconditioning (rRIC) on doxorubicin-induced cardiotoxicity in mice.
Quan He, PhD, Fangfei Wang, MD, Thomas D. Ryan, PhD, MD, Meghana Chalasani, BS, Andrew N. Redington, MD   +4 more
doaj   +1 more source

A switching mechanism in doxorubicin bioactivation can be exploited to control doxorubicin toxicity.

PLoS Computational Biology, 2011
Although doxorubicin toxicity in cancer cells is multifactorial, the enzymatic bioactivation of the drug can significantly contribute to its cytotoxicity. Previous research has identified most of the components that comprise the doxorubicin bioactivation
Nnenna A Finn, Harry W Findley, Melissa L Kemp   +2 more
doaj   +1 more source

Inhibition of Autophagy Promotes the Elimination of Liver Cancer Stem Cells by CD133 Aptamer-Targeted Delivery of Doxorubicin

Biomolecules, 2022
Doxorubicin is the most frequently used chemotherapeutic agent for the treatment of hepatocellular carcinoma. However, one major obstacle to the effective management of liver cancer is the drug resistance derived from the cancer stem cells.
Wang Yin, Cuong V. Pham, Tao Wang, Hadi Al Shamaileh, Rocky Chowdhury, Shweta Patel, Yong Li, Lingxue Kong, Yingchu Hou, Yimin Zhu, Sunrui Chen, Huo Xu, Lee Jia, Wei Duan, Dongxi Xiang   +14 more
doaj   +1 more source

Overexpressed SIRT6 ameliorates doxorubicin-induced cardiotoxicity and potentiates the therapeutic efficacy through metabolic remodeling

Acta Pharmaceutica Sinica B, 2023
Since the utilization of anthracyclines in cancer therapy, severe cardiotoxicity has become a major obstacle. The major challenge in treating cancer patients with anthracyclines is minimizing cardiotoxicity without compromising antitumor efficacy. Herein,
Kezheng Peng, Chenye Zeng, Yuqi Gao, Binliang Liu, Liyuan Li, Kang Xu, Yuemiao Yin, Ying Qiu, Mingkui Zhang, Fei Ma, Zhao Wang   +10 more
doaj   +1 more source